### Brief profile of the selected companies

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Particulars</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Introduction</td>
</tr>
<tr>
<td>4.2</td>
<td>Sun Pharmaceutical Industries</td>
</tr>
<tr>
<td>4.3</td>
<td>Lupin pharmaceutical</td>
</tr>
<tr>
<td>4.4</td>
<td>Dr. Reddys Laboratories</td>
</tr>
<tr>
<td>4.5</td>
<td>Cipla pharmaceutical industries</td>
</tr>
<tr>
<td>4.6</td>
<td>Aurobindo Pharma Company</td>
</tr>
<tr>
<td>4.7</td>
<td>Cadila Healthcare</td>
</tr>
<tr>
<td>4.8</td>
<td>Glenmark Pharma</td>
</tr>
<tr>
<td>4.9</td>
<td>GlaxoSmithKline Pharmaceuticals</td>
</tr>
<tr>
<td>4.10</td>
<td>Divis Laboratories</td>
</tr>
<tr>
<td>4.11</td>
<td>Torrent Pharmaceuticals</td>
</tr>
</tbody>
</table>
4.1 Introduction

India is the world's third largest pharmaceutical industry in terms of volume and world's 13th largest pharmaceutical industry by value. The top 8 to 10 companies including Sun Pharma, Lupin, Dr. Reddy’s Labs and Cipla occupy 70 to 80 percent of the Indian pharmaceutical market space. It is estimated by a Fitch Group company named India Rating that the Indian pharmaceutical industry will grow at a rate of 20 percent during 2015-2020. The domestic market is expected to do better this time as the projected growth rate is 10-12 percent during 2015-16 as compared to 9 percent in 2014-15.

List of Top 10 Pharmaceutical Companies in India

Here are the top pharmaceutical companies in India in terms of their market capitalisation:

1. Sun Pharmaceutical

Sun Pharma, officially known as Sun Pharmaceutical Industries Limited, was founded in 1983 by Dilip Shanghvi. The company is headquartered in India's financial capital Mumbai, Maharashtra. Active Pharmaceuticals Ingredients (APIs) and formulations are known to be Sun Pharma's specialised areas. It targets a wide spectrum of chronic and acute treatments. Its therapeutic segments of over 3000 high quality molecules include psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. On 15 June 2015, Sun Pharma was India's largest pharmaceutical company with the market capitalisation valued at Rs. 2,01,706.41 crore. Its products and services may be categorised as below:

- Formulations
- Active Pharmaceutical Ingredients (APIs)
- Over-The-Counter (OTC)
- Antiretrovirals (ARVs)
2. Lupin

Headquartered in Mumbai, Lupin Limited is a multinational pharmaceutical company. An associate professor at BITS-Pilani in Rajasthan, Dr. Desh Bandhu Gupta established Lupin in 1968, which is today one of India's leading pharmaceutical companies. In Pune, Maharashtra, Lupin has a state-of-the-art research and development unit. It is one of the fastest growing companies as far as oncology, cardiology, gastroenterology, central nervous system, anti-infective, anti-asthma and diabetology therapies are concerned. Lupin's market capitalisation amounted to Rs. 77,115.19 crore on 15 June 2015. Its products and services may be categorised as below:

- Branded Formulations
- Advanced Drug Delivery Systems
- Generics
- Novel Drug Discovery
- APIs
- Biotechnology

3. Dr. Reddy's Labs

Based in Hyderabad, Telangana, Dr. Reddy's Laboratories is a multinational pharmaceutical entity. It was founded in 1984 as a manufacturer of APIs. A vast range of pharmaceutical products are offered by Dr. Reddy's Labs. It has 60 APIs and 190 medications to treat various kinds of ailments. It is now India's third largest pharmaceutical company in terms of market capitalisation, which was valued at Rs. 56,638.13 crore on 15 June 2015. Its products and services may be categorised as below:

- Generic Formulations
- Active Ingredients
- Pharmaceutical Services
- Biosimilars
- Propriety Product
4. **Cipla**

Dr. K. A. Hamied set up Cipla Limited in 1935, which is one of the biggest biotechnology and pharmaceutical multinational companies of India today. APIs and formulations are produced at 34 state-of-the-art Cipla plants spread across the country. Primarily, medicines for treatments of ailments like depression, obesity, cardiovascular diseases, arthritis and diabetes are developed by Cipla. It is India's fourth largest pharmaceutical company accounting for a market capitalisation worth Rs. 47,025.38 crore on 15 June 2015. Its products and services may be categorised as below:

- APIs
- Formulations
- Veterinary

5. **Aurobindo Pharma**

Aurobindo Pharma was founded by K. Nityananda Reddy and P.V. Ramaprasad Reddy with others in 1986. Headquartered in Hyderabad, Telangana, Aurobindo Pharma Limited manufactures APIs and generic pharmaceuticals. Six prime therapeutic areas of medication addressed by the company are anti-allergic, gastroenterology, antiretrovirals, antibiotics, central nervous system and cardiology. With the market capitalisation valued at Rs. 37,281.76 crore on 15 June 2015, Aurobindo Pharma Limited is India's fifth largest pharmaceutical company. Its products and services may be categorised as below:

- Formulations
- APIs

6. **Cadila Healthcare**

The city of Ahmedabad in the western Indian state of Gujarat is home to the head office of Cadila Healthcare that was founded in 1952. The company has around 20 different manufacturing locations across the country. Cadila Healthcare is India's sixth largest pharmaceutical company in terms of market capitalisation that amounted to Rs. 36,159.61 crore on 15 June 2015. Its products and services may be categorised as below:

- APIs
7. GlaxoSmithKline

One of the oldest and most experienced players in the pharmaceutical industry of India, GlaxoSmithKline Pharmaceuticals Limited was established in 1924. GlaxoSmithKline Pharmaceuticals is one of the world's top research-based health management and pharmaceutical companies. Major therapeutic areas of medication addressed by the company are anti-infectives, dermatology, oncology, gynaecology, diabetes, cardiology and respiratory products. In addition to that, it provides vaccines for cervical cancer, hepatitis B, hepatitis A, rota-virus, influenza, tetanus, chickenpox, pertussis and diphtheria amongst many. The market capitalisation of GlaxoSmithKline Pharmaceuticals Limited stood at Rs. 27,522.55 crore on 15 June 2015.

8. Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is an Indian pharmaceutical company founded in 1977 and headquartered in Mumbai, Maharashtra. It specialises in developing and marketing APIs and formulations and covers segments such as diabetology, dermatology, ENT, internal medicine, gynaecology and paediatrics. Glenmark Pharmaceuticals is India's eighth largest pharmaceutical entity by market capitalisation, which was valued at Rs. 25,045.36 crore on 15 June 2015. Its products and services may be categorised as below:

- Formulations
- Active Pharmaceutical Ingredients

9. Divi's Laboratories

Divi's Laboratories was set up in 1990 with the sole purpose of research and development in the life-sciences segment. The company mainly focuses on the development of modern innovative methods of manufacturing pharmaceutical intermediaries and other APIs. It is India's ninth largest pharmaceutical company by market capitalisation, which amounted to Rs. 23,493.97 crore on 15 June 2015. Its products and services may be categorised as below:
• Generics
• Intermediates
• Protected Amino Acids
• Chiral Synthesis
• Carotenoids (Synthetic) and Nutraceuticals

10 Torrent Pharmaceuticals

Based in Ahmedabad, Gujarat, Torrent Group’s flagship unit is Torrent Pharmaceuticals, founded in 1959. It is a major in therapeutic realms such as central nervous system and cardiovascular, spanning over segments like diabetology, gastroenterology and anti-infectives to name some. Torrent Pharmaceuticals is operational in over 50 countries and has a significant presence in India where it is rated as one of the top 10 pharmaceutical companies operating in the country. On 15 June 2015, the market capitalisation of Torrent Pharmaceuticals was Rs. 21,555.59 crore.

Some other leading pharmaceutical companies:

• Aventis Pharma
• GlaxoSmithKline
• Surya Pharma
• Torrent Pharma
• Glenmark
• Divis Labs
• Biocon
• Orchid Chemical
• Abbott India
• Sterling Bio
• Alembic Pharma

Last Updated on June 24, 2015 pharmaceutical Companies in India

• Pharmaceutical Industry
• Role of pharmaceutical industry
Globalization of Pharma
Biotech Companies
Aurobindo Pharma
Aventis Pharma
Biocon
Cadila Healthcare
Cipla
Dabur
Dishman Pharmaceuticals
- Divi's Laboratories
- Dr. Reddy's Laboratories
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Ipca Laboratories
- JB Chemicals & Pharmaceuticals
- Nicholas Piramal
- Ranbaxy Laboratories
- Strides Arcolab
- Sun Pharmaceuticals
- Torrent Pharmaceuticals

4.2 Sun Pharmaceutical Industries
Business Development

With global revenues of over US$ 4.5 billion, Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide. Sun Pharma is also India’s largest and most trusted pharmaceutical company. Our global presence is supported by 45 manufacturing facilities across 5 continents.

In the US market, which contributes a significant share of our revenues, we are the leader in the generic dermatology segment. We have strong capabilities in developing generic and complex products with a robust pipeline of 149 ANDAs, including high value First-to-File (FTF) opportunities. We have an established presence in Europe and key high-growth emerging markets like Russia, Romania, South Africa, Brazil and Malaysia.

Develop of the Sun Pharmaceutical Industries

1983 - The Company was incorporated as a partnership firm by Dilip Sanghvi & his family to manufacture pharmaceutical formulation at Vapi Gujarat. It was converted into a public Ltd. Company effective 1st March. The was promoted by Dilip Sanghvi. The Company specialises in selected therapeutic segment to psychiatry, cardiology, neurology and gastroenterology.

2002 - Caraco Pharmaceutical Laboratories, associate of Sun Pharmaceuticals, has
received US Food and Drug Authority (FDA) preliminary approval for metformin hydrochloride, a molecule used to treat diabetes.

**2004** - The formulation site in Halol, India (the erstwhile MJ Pharma site) receives approval from USFDA, UK MHRA, South African MCC, Brazilian ANVISA and Columbian INVIMA. The BT Stern Stewart survey places Sun Pharma among the top 20 wealth creators in India and among the top 3 wealth creators in the pharma sector. Construction at a formulation manufacturing site at Jammu is completed. Our first joint venture manufacturing unit, in Dhaka, Bangladesh is commissioned.

**2012** - Sun Pharma bagged USFDA approval for its AND Application for generic ZIsrael Makov appointed Chairman of Sun Pharma Board Sun Pharma acquired URL generic business from Taked The Norwegian firm Telenor conduct its operations in India, promoters of Sun Pharma emerged as the new JV partner of the company.

**2014** - Sun Pharma announces US FDA approval for generic Temodar. Sun Pharma acquires Pharmalucence. Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transaction.

**2015** - Sun Pharma receives US FTC clearance for Ranbaxy acquisition Sun Pharma and AstraZeneca enter into distribution agreement for icagrelor in India. SPARC Licenses Xelpros (Latanoprost BAK-free) to Sun Pharma. Hon’ble High Court of Gujarat, at Ahmedabad has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company. Sun Pharma announces US FDA Approval for Ximino TM. Sun Pharma announces successful completion of Opiates business acquisition in Australia. Sun Pharma announces Absorica patent litigation settlement. Sun Pharma Successfully Acquires Insite Vision.

*(Source: Dion Global Solutions Limited)*
4.3 – Lupin pharmaceutical

Regd. Office

Address: Kalpataru Inspire, 3rd Floor,
District: Mumbai
State: Maharashtra
Pin Code: 400055
Tel. No.: 022-66402323
Fax No.: 022-26528806
Email: investorservices@lupin.com
Internet: http://www.lupin.com

Mission/Vision

Lupin's mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.

Our Vision

Lupin Pharmaceuticals, Inc. is committed to bringing innovative products for the healthcare professional to improve the health and well being of individuals.

Lupin Pharmaceuticals, Inc. is well positioned for growth in the US market. We can capitalize on the strengths of our parent company, Lupin Limited:

• Scientific expertise to develop new and improved products and product line extensions;
• Manufacturing technology, expertise and infrastructure;
• Financial resources.
**Business Development**

Lupin was founded to meet the very basic need for effective treatment of tuberculosis. Our success is tied to continually meeting the need for basic products to promote human health. Our company strives to bring important new products to market each year. We expect our products to come from:

- In-house product development
- Licensing and acquisitions
- Marketing alliances

Lupin is also seeking to be the partner of choice for product development. Our scientists apply know how and expertise to develop NCE's or to solve difficult formulation challenges. We strive for continued growth and are avidly interested in learning about prospective opportunities in the specialty pharmaceutical market. We are also open to collaborating to develop innovative products formulated with Lupin's drug delivery and taste masking technology. Our API business unit is seeking partners for Lupin developed API's.

**Devlop of the Lupin pharmaceutical**

Lupin Chemicals Ltd (LCL) was promoted by Lupin Laboratories Ltd. The company was incorporated on 31.03.83 as a Private Ltd company and subsequently converted into a Public Ltd company with effect from 23.12.91. The company does not have any subsidiary. The company is setting up a project for the manufacture of 93 tpa of Rifampicin, an essential anti-tuberculosis, anti-leprotic, life saving drug from a very basic stage of fermentation. It is an import substitute product. To finance the project the company is coming out with a PCD issue aggregating to Rs.45.6 crores.

**2002** - Lupin Ltd has successfully introduced AkuriT, a revolutionary simplified therapy as per WHO are guidelines for treatment of tuberculosis. Crisil has upgraded the rating assigned to Lupin's non-convertible debentures from D to BB+. Lupin Ltd has enhanced its capacity of manufacturing various products at its formulations plants at Aurangabad and Manideep in Madhya Pradesh.
2004 - Mr. Dhawan will be responsible for the development of Lupin's business strategy for these markets, with focus on, among others, product selection, entry strategy, marketing and sales, and regulatory compliance. Lupin Limited has informed that at the EGM of the Company held on December 05, 2003, the members of the Company have by means of a special resolution determined to delist shares of the Company, from the following exchanges: 1) The Calcutta Stock Exchange Association Ltd. 2) The Stock Exchange, Ahmedabad, 3) Jaipur Stock Exchange Ltd., 4) The Delhi Stock Exchange Association Ltd. The Company has initiated action to secure de-listing of the equity shares of the Company, from the aforesaid exchanges. The Equity shares of the Company are listed on the NSE and BSE and will continue to be listed and traded on NSE and BSE. Floats new division - Lupin Herbal, dedicated to research-based phytomedicines. Unveiled nine herbal products in therapeutic areas, including diabetes, pediatrics, gastro intestinal, pain management and gynaecology.

2007 - Lupin Receives US FDA Approval for Simvastatin Tablets. Lupin gets MHRA Approval for Lisinopril in UK. Lupin Ltd has announced that it has received Euro 20 million from Laboratoires Servier of France for the sale of additional patent rights for Perindopril. Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for its herbal Psoriasis NCE. Lupin Ltd on April 27, 2007, has announced that Department of Science and Technology (DST), Government of India and the Company have joined hands for the clinical development of the Company's Migraine and Psoriasis projects. Lupin receives Best New Manufacturer of the Year Award from AmerisourceBergen.

2009 - Lupin receives US FDA approval for Levetiracetam Tablets. Lupin ties up with leading Institutes for PhD Program. Lupin in Equity Partnership with Multicare Pharmaceuticals Philippines, Inc. Lupin Expands Branded Play, Announces Acquisition of Worldwide Rights for its first NDA – AllerNaze.

2010 - Lupin Limited has launched Ilyalgan (sodium hyaluronate), an osteoarthritis drug, available in the form of an injectable through leading orthopaedics and physiotherapists across the country. Hyalgan 40 is the original research molecule of the Italian pharma giant I-IDIA and is the world leader in HA therapy, marketed in over 60 countries globally. Lupin Limited's U.S subsidiary, Lupin Pharmaceuticals Inc. (LPT) has received the final approval for the
company's Abbreviated New Drug Application (ANDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg from the U.S. Food and Drug Administration (FDA). Commercial shipments of the product have already commenced.

2013 - Inauguration of new Plant at Nagpur. Mahindra Samridhhi India Agri National Award for Bee keeping and Honey Production. NABARD's BEST NGO Award to MSGD, Alwar for promotion and linkages of Self Help Groups in the state.


(Source : Dion Global Solutions Limited)

4.4 Dr. Reddys Laboratories
Our patients trust our medicines and we believe that this trust must be earned every single day. We continually remind ourselves that the interests of our patients must always come first. In pursuit of this, we believe in creating an environment of innovation and learning, as we push ourselves to reach higher levels of excellence.

- **Integrity and Transparency**: We will uphold the highest standards of integrity and transparency in all our interactions.
- **Safety**: We are committed to providing safe working environments through continuous improvement of our infrastructure, work practices and behaviors.
- **Quality**: We are dedicated to designing quality into our products and processes to delight our stakeholders.
- **Productivity**: We strive to achieve more with less through a culture of innovation, continuous improvement and a sustained focus on elimination of waste.
- **Respect for the Individual**: We are committed to providing a work environment that encourages diverse perspectives and upholds the dignity of work and of individuals.
- **Collaboration and Teamwork**: We will leverage expertise and resources from across our global network to create greater value for our stakeholders.
- **Sustainability**: We will create value for all our stakeholders in a manner that respects our natural environment and serves the best interest of the communities in which we live and work.
Develop of the Dr. Reddys Laboratories

1989 - An explosion at the Company's plant resulted in stoppage of production for 2 months. Two new products namely, a Ciprolet and Enam were introduced by the Company's formulation division while the Company's bulk drug division commenced manufacture of ciprofloxacin, a new drug.

1999 - Dr. Reddy's Laboratories are setting a new trend in the Indian pharmaceutical sector by installing a 'satellite' discovery research laboratory in the United States. The company has two US-FDA approved plants. It has been exporting its products to the UK, Switzerland, Germany, Spain, Italy and the Netherlands. It also started exporting its formulations in a big way to Russia and has set up an office there. DRL has signed a joint venture agreement with the Khetan group, Nepal, for setting up a joint venture for the manufacture and marketing of finished formulations in Nepal and other neighboring countries. It also signed a marketing and distribution agreement with Organics, Israel, for a wide range of sophisticated diagnostic kits. The products are recognized by WHO and other leading organizations in the healthcare industry.

2011 - Dr. Reddy's announces the launch of Pantoprazole Sodium delayed-released tablets. Dr Reddy's launches generic allergy drug in US. Dr. Reddy's announces completion of the acquisition of US penicillin facility and products from GlaxoSmithKline.

(Source: Dion Global Solutions Limited)

4.5 Cipla pharmaceutical industries
Our Businesses

The commitment to high quality standards has made Cipla the most trusted brand among healthcare professionals. Cipla today has 12 divisions reaching out to more than 20 specialties from general-practioners to super-specialists. Cipla is a market leader in three therapies — Respiratory, Urology and Antiretroviral (ARV) with seven brands in the top 100 list. In the fiercely competitive Indian pharmaceutical industry environment, Cipla scores over with strong brand equity, product range, unique dosage forms, pioneering work across therapeutic areas, numerous medico-marketing initiatives, strong distribution network of distribution depots catering to a network of over 3,000 stockists, reaching out to 7,00,000 chemists and more than 10,000 colleagues with can-do attitude. Cipla’s approach is to understand unique patient requirements and develop solutions, and also focus on enhancing patient awareness and medical education.

“At Cipla, we believe our work is not just about making medicines, it’s about making a difference”

Develop of the Cipla company

Cipla was born out of Dr. K.A. Hamied’s vision to harness Indian expertise for self-sufficiency in the chemical and pharmaceutical industry in India. Dr. K.A. Hamied was an exemplary visionary who donned various hats; he was a chemist, an entrepreneur and pioneer, an active participant in India’s independence struggle, a close ally of Mahatma
Gandhi, Dr. Zakir Hussain and various others, a legislator in the Bombay Presidency, head of various associations, Sheriff of Bombay, proactive supporter and sponsor of institutes of scientific excellence in India.

Be it the commencement of bulk drug production in India, the landmark Indian Patents Act of 1970, the several ‘firsts’ in India and the world, its historic international stance on the price and availability of antiretroviral drugs for HIV treatment in 2000-2001, its free-of-cost Palliative Care Centre for terminally-ill cancer patients, Cipla, under the leadership of its current Chairman Dr. Y.K. Hamied, has stood for fearlessness and compassion. It is not for nothing that we say ‘None Shall is Denied’. Apart from its various national and international milestones, the story of Cipla’s growth and expansion, its ups and downs, successes and challenges is also one that deserves to be chronicled. According to Dr Y K Hamied, Cipla was ranked 56 in the 1960s.

It is with this view that the Cipla Archives project has been launched recently. We treat our proud legacy with the seriousness and the sense of responsibility it deserves. We want to share Cipla’s story, celebrate its rich history, remind ourselves of the lessons learned, and reflect on the evolution of the pharmaceutical industry in India and at Cipla’s role in shaping it.

The Cipla Archives will bring together and house a treasure-trove of documents, photographs and oral history interviews, among other material. As the project progresses, we hope to make information available through this website. With this initiative and related activities, we not only hope to showcase Cipla’s history but also contribute to the development of business archives in India, and serve as a forum for debates and discussions on the history and historiography of science and the pharmaceutical industry in India.

1935 - The Company was Incorporated at Mumbai.

1987 - The Company launched several new products viz., Asthalin and Beclate Rotahalers/Rotacaps-dry powder inhalation devices for asthma, presolar capsules, the first synergistic combination of a beta blocker and a sustained release calcium channel
blocker for hypertension, Restyl tablets, the first anxiolytic-cum-anti depressant, Theo-
Asthalin SR tablets, the first sustained release combination of two widely used bronchodilators, bromolin dry syrup and bromolin-250 capsules, antibiotic-cum-
mucolytic agents, dilgard tablets, a new calcium channel blocker for angina, ibugesic plus suspension, a non steroidal, anti inflammatory and anti-pyretic analgesic for paediatric use.

1990 - The Company launched several new products viz., Aerocort inhaler, an anti-
inflammatory bronchodilator, Norflox eye/ear drops, a broad spectrum fluoroquinolone antibacterial, Pirox Gel, the first topical piroxicam formulation in the country, Cofenac tablets – an anti-inflammatory analgesic, Kinetal 400 tablets, a multi-functional drug for vascular insufficiency, Novaclox Ped tablets, a dispensible combination antibiotics, Terfed tablets and Suspension, a new non-sedative antihistamine, Depryl tablets, a broad spectrum antidepressant, Asthalin Respirator Solution, a bronchodilator for pressure ventilation in acute asthma.

1992 - Some of the new products introduced were Zidovir capsules an antiretroviral for HIV injection, Cipril tablets for hypertension, Optipres eyedrops for glaucoma patients, Felogard for hypertension, Nodine, a non-narcotic analgesic, etc.

1995 - The Company initiated steps to mitigate the impact it could have on production. New products introduced were - Acivir - antivirus herpes, Anlopres antiviral herpes, Anlopres, Calcium channel blocker in hypertension and angina, Anlopres AT, a combination antihypertensive, Budecort 200, a higher strength corticosteroid in bronchial asthma, Budenase AQ, a corticosteroid protection in allergic rhinitis, cronial, a nast cell stabiliser in allergic conjunctivitis, cytonid, a antiandrogenic agent in prostate cancer, Norflox, an antidiarrhoeal in diarrhoea of mixed origin, optipes S - betaxocol eye drops, profenac, anti-inflammatory eye drops, Terfed D - a combination antihistamine and decongestant, Trivedon 20 - used in ischaemic heart disease.

1997 - The products introduced during the year were, Alerid-D – an antihistamine and decongestant for cold and congestion, Amlopres L, a tablet for hypertension, Apuatears,
an eye drop, Azee 1000, a single dose for STDs, Budecort Respules, neubulised corticosteroid therapy for asthma, Dilgard XL, a diltiazem, Glumet, tablet for obese diabetics, Glygard - tablet for obese diabetics, Glygard - tablet for diabetics, Ipranase AQ (ipratropium nasal spray), an anticholinergic therapy for rhinorrhoea, Ocutilm (an eye drop), a glaucoma therapy in acquafilm formulation, Osteifos 10, tablet for osteoporosis, Prolyte Fizz, a rehydration effervescent tablet, Pylokit an advanced Hpylori kit, Rinsia, an a typical antipsychotic, Stavir, an antiretroviral for AIDS, Synclar 250 an advanced macrolide antibiotic, Theoday a tablet for asthma, Zoflut Lotion, a topical corticosteroid.

1999 - Ranbaxy and Cipla have entered into a strategic partnership to jointly market a select basket of drugs. The alliance will bring forth their strengths in the strongly emerging cardiovascular and perennial anti-infectives market. As a first step, the two molecules being jointly launched are Carvedilol, a new generation anti-hypertensive and Cefpodoxime Proxetil, an advanced third generation oral cephalosporin.

2003 - Applies its requisiton for Abbreviated New Drug Application (ANDA) with US regulators for a post-menopausal drug, National Pharmaceutical Pricing Authority (NPPA) issues notices to Cipla along with Ranbaxy for overcharging the products Completes research studies on three Anti-HIV Drugs, Registers Stavudine, Nevirapine, other anti-AIDS products in South Africa

2005 - Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. Cipla introduces new drug for arthritis, Cipla to sign deal with Akorn Inc for anti-infective drug, Cipla to produce generic versin of bird-flu drug.

2009 - Cipla wins Erlotinib case against Roche, Pharmaceuticals Export Promotion Council Awards, Cipla launches drug to treat Swine flu virus, and Cipla wins patent fight against Gilead Sciences. Drug Maker Cipla has launched the generic Version of Pirfenidone, used to treat Idiopathic Pulmonary Fibrosis, a progressive Lung disease. India is the 2nd market to have this drug after Japan.

2012 - Cipla India's second largest drug firm, has agreed to acquire South African Drugmaker Cipla Medpro with 51% stake amounts to 0 Million. Cipla bags tentative
approval for HIV treatment tablets. Drug giant Cipla Ltd has announced price reduction on 3 major anti-cancer drugs including Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). Cipla bags award in the Field of Export of Pharmaceuticals during the year conferred the Highest Award 'Platinum'.

2014 - Cipla wins USD 188.95 million of Global Fund ARV Tender, MMV announces collaborations with Cipla and Strides, Cipla licenses rights for innovative product, Cipla, S&D Pharma collaborate to enter Czech Republic and Slovakia, Cipla collaborates with Hetero to launch its second biosimilar drug ‘Darbepoetin alfa’. Cipla invests in Chase Pharmaceuticals to support Alzheimer’s disease drug development.

2015 - Cipla Ltd has entered into an agreement with partner, Biopharm SPA, to form a joint venture (JV) company in Algeria. Cipla Ltd has launched the generic drug Sofosbuvir in brand name Hepcvir, Cipla Ltd has inked an agreement with Serum Institute of India Ltd. (SII) to market flu vaccine Nasovac-S. Cipla Ltd has entered into a definitive agreement with Biopharma SPA for establishing a joint venture company in Algeria. Cipla Ltd has launched an anti-ageing skin care product Cutisera&trade. Developed by Stempeutics Cipla has launched generic tablets used for treating of hepatitis C under the brand name Hepcvir-L.

(Source : Dion Global Solutions Limited)

4.6 Aurobindo Pharma Company
**Registered Address**
Plot No. 2, 
Maitrivihar, Ameerpet, 
Hyderabad 
Telangana 
500038 
Tel: 040-23736370 
Fax: 040-23746833 040-23747340 
Email: info@aurobindo.com 
Website: http://www.aurobindo.com 
Group: Not Applicable

**Registartors**
Karvy Computershare Private Ltd, 
Karvy Selenium Tower B, 
Plot no. 31-32, Gachibowli 
Financial District Hyderabad - 500032 
Telangana 
Tel: 040-23001153

**VISION**
"To become Asia's leading generic Pharma Company and one among the top 15 in the world, by 2015".

**MISSION**
Aurobindo's mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.

**OUR VALUES**

---

**Business Care**
- Operational Excellence
- Stakeholder orientation
- Quality, Innovation

**People Care**
- Fairness, Humility & Respect for individuals
- Teamwork, synergy
- Applied Learning

**Organization Care**
- Accountability
- Integrity
- Achievement
Develop of the Aurobindo Pharma company

1986 - The company was incorporated on 26th December as a Private Limited company and was converted into a Public Limited company with effect from 30-4-1992. The company is registered with the Registrar of Companies, Andhra Pradesh at Hyderabad. The chief promoters of the Company are Shri P.V. Ramaprasad Reddy and Shri K. Nityananda Reddy. Aurobindo Pharma Limited is one of the leading manufacturers of life saving anti-biotic bulk drugs in India with excellent track record of profitability and growth. The Company has developed inhouse technology for manufacture of the bulk drugs as well as formulations.

1993 - The Company has set up two more units during the year, viz., i) Bulk drug unit at Bollaram, near Hyderabad, ii) Formulations unit at Kukatpally, near Hyderabad. The Company is setting up a Bulk Drug cum Formulation Plant to produce sterile Bulk Drugs like Ampicillin Sodium (Sterile) IP/BP, Cloxacillin Sodium (Sterile) IP/BP, and cephalosporins (Sterile) Bulk Drugs and Formulations in the dosage forms like sterile powder Injectables, small volume parenterals, Capsules and Tablets.

1994 - The Company has agency set-up at Srilanka, Thailand, Russia and Nigeria for marketing its products. It proposes to set up its own marketing offices at Hongkong, Moscow and Nigeria to promote bulk drug sales.

1997 - Glaxo (India), the Indian subsidiary of the UK-based multinational, is understood to be negotiating with the Hyderabad-based Aurobindo Pharma for an alliance to meet its global bulk drug requirements. The annual capacities now stand at 300 million of capsules and 840 tonnes of bulk drugs.

1999 - Aurobindo currently manufactures three types of drugs including cephalosporin-based formulations, drugs for gastroenterology and pain-related products. The company proposes to deploy the issue proceeds to part-finance its R&D thrust and the growth of its formulations business. APL plans to meet the further funds requirement for its capital
expenditure programme, if any, through internal accruals. Aurobindo Pharma Ltd, the largest domestic manufacturer of penicillin-based bulk antibiotics, plans to form joint ventures in Brazil and China by the end of financial year 1999-2000 (April-March).

**2001** - This new structure is expected to enable the company to concentrate on the strategies of change being pursued by it to achieve the goal of becoming a research and development-based international pharmaceutical company, it said, adding that the changes had received board approval.

**2003** - Aurobindo Tongling (Datong) pharmaceuticals Ltd, China, a JV between APL and Shanxi Tongling Pharmaceuticals co. has set up for manufacture of pharmaceutical products for the local market. With a view to manufacture Pen G, a raw material essential for the production of semi-synthetic pencillin, Aurobindo has infused Rs 59cr in a flagship Aurobindo (Datong) Pharma Ltd. Aurobindo Pharma has launched second joint venture company in US for the purpose of Research and Development. Aurobindo Pharma has launched second joint venture company in the United States for the purpose of R & D in alliance with Salus Pharmaceuticals. Aurobindo Pharma has filed around 20 patents in the areas of central nervous system, cardio-vascular, and anti-cholesterol segments. Out of this it is able to obtain 2 of them in United States of America.

**2004** - Aurobindo Pharma Ltd has announced that it has received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology.

**2011** - Aurobindo Pharma Announces Strategic Divestment of Aurobindo (Datong) Bio Pharma, China, Aurobindo Pharma receives USFDA tentative approval for Levofoxacin Tablets, Aurobindo Pharma receives USFDA tentative approval for Venlafaxine Extended Release Capsules, Aurobindo Pharma receives USFDA tentative approval for Famclovir Tablets, Aurobindo Pharma receives Platinum Certificate of Outstanding Exports Award from Pharmexcil.

**2013** - Aurobindo Pharma gets USFDA approval for anti-migraine tablets. Aurobindo Pharma receives tentative approval for Efavirenz/Emtricitabine/Tenofovir Disoproxil
Fumarate Tablets. Aurobindo gets final USFDA approval for Cefadroxil oral suspension. Aurobindo Pharma bags final US FDA approval for Rizatriptan Benzoate ODT.


2015 - Aurobindo Pharma has received approval from the USFDA to manufacture and market Valsartan Tablets USP, Aurobindo Pharma gets USFDA nod for Lacosamide Tablets, Aurobindo Pharma receives USFDA Tentative Approval for Lacosamide Tablets, Aurobindo Pharma gets USFDA nod for Lacosamide Tablets, Aurobindo Pharma gets USFDA nod for Sildenafil injection, Aurobindo gets USFDA nod for Atracurium Besylate injections, Aurobindo Pharma receives USFDA Approval for Cefixime for Oral Suspension USP, Aurobindo Pharma receives USFDA approval for Famotidine Tablets.

(Source: Dion Global Solutions Limited)

4.7 Cadila Healthcare

Registered Address
"Zydus Tower",
Satellite Cross Roads,
Sarkhej Gandhinagar Highway
Ahmedabad

Registrars
Sharepro Services (India) Pvt.Ltd.
13 AB, Samhita Warehousing Complex,
2nd Floor, Sakinaka Telephone Exchange Lane, Off Andheri-Kurla Road,
Vision

“Our vision is to be a leading pharmaceutical company in India and to become a significant global player by providing high quality, affordable and innovative solutions in medicine and treatment.”

Mission

“We will discover, develop and successfully market pharmaceutical products to prevent, diagnose, alleviate and cure diseases.

We shall provide total customer satisfaction and achieve leadership in chosen markets, products and services across the globe, through excellence in technology, based on world-class research and development.

We are responsible to the society. We shall be good corporate citizens and will be driven by high ethical standards in our practices.

Develop of the Cadila Healthcare Company

1995 - The Company was incorporated as Cadila Healthcare Private Ltd. On May 15, under the company act, 1956 and subsequently the Company was converted into a public company and then renamed as Cadila Healthcare Ltd. effective from July 17, 1996. The name Cadila shall be used only for Cadila Healthcare Limited (Zydus Cadila), Cadila Pharmaceuticals Limited (CPL) and Cadila Laboratories Limited (CLL). The Company's operations include pharmaceuticals (human formulations, veterinary formulations and bulk drugs), diagnostics, herbal products, skin care products and other OTC products. The Company has 6 subsidiaries Indon Healthcare Ltd., Zydus Pharmaceuticals Ltd., Zudus Agrovet Ltd., and Zoom Properties Pvt. Ltd., Zydus International Pvt. Ltd., Ireland and

1998 - Zydus Cadila signed an agreement with Apotex SA Pty. Ltd. for manufacturer of Amoxycillin, Ampicillin, Co-trimoxazole, paracetamol. Zydus Cadila has also entered into a joint venture with Korea Green Cross Corporation, Korea, to manufacture and market recombinant Hepatitis B vaccine in India.

2001 - Cadila Healthcare has signed a three year collaborative R&D agreement with Danish biotech company Pantheco in the field of anti-bacterials. The neurosciences division launched by the company has introduced anxiolytic paroxetine for the first time in the country. The name Cadila shall be used only for Cadila Healthcare Limited (Zydus Cadila), Cadila Pharmaceuticals Limited (CPL) and Cadila Laboratories Limited (CLL). The Company's operations include pharmaceuticals (human formulations, veterinary formulations and bulk drugs); diagnostics, herbal products, skin care products and other OTC products. The Company has 6 subsidiaries Indon Healthcare Ltd., Zydus Pharmaceuticals Ltd., Zudus Agrovet Ltd., Zoom Properties Pvt. Ltd., Zydus International Pvt. Ltd., Ireland and Zydus Healthcare S.A. (Pvt) Ltd., South Africa.

1996 - Zydus Cadila signed an agreement with Centeon L.L.C., USA and Centeon Pharma GMBH, Germany for Exclusive rights to sell and distribute plasma products in India and Nepal.

1999 - The Company has set up a joint venture company to manufacture the break-through molecule Pantoprazole. The Company is also undertaking discovery research projects with Byk Gulden as a pan of the Joint Venture. The Company has entered into a technical-cum-marketing tie-up with the Swiss Serum and Vaccine Institute, Berne, Institute to launch a range of vaccines in India. The Company has entered into a joint venture with the Haffkine institute to undertake research in the field of human vaccine and equine sera.

2000 - The Company is setting up wholly owned subsidiaries abroad and plans to acquire overseas companies to market products. The Company has entered into License Agreement for phased manufacture and technical know-how transfer with Swiss Serum and Vaccine
Institute, Switzerland for the manufacture of Purified Cuck Embroy Vaccine. The Country's fifth largest pharmaceutical company is considering offering stocks to its employees through an employees' stock option scheme. The Company has formed a JV Company in the name of Zydus Byk Healthcare Limited with an equal participation in collaboration with Byk Gulden Lomberg Chemische Fabrik GmbH, Germany, for manufacturing of Bulk Drugs, Formulations and R & D. Cadila Healthcare Ltd is setting up wholly owned subsidiaries abroad and plans to acquire overseas companies to market products.

2001 - Cadila Healthcare has signed a three year collaborative R&D agreement with Danish biotech company Pantheco in the field of anti-bacterials. The neurosciences division launched by the company has introduced anxiolytic paroxetine for the first time in the country.

2003 - Cadila Healthcare receives Mumbai High court approval for the scheme of amalgamation with German Remedies Ltd and Zoom Properties Ltd. Zydus Cadila Healthcare Ltd has signed a pact with Schering AG, Germany which allows the Indian Pharmaceuticals major to market Schering's patented products in India. Duphar Interfran, a subsidiary of Fermenta Biotech Ltd sagiaaement with Cadila Ltd for the sale of FBL's global patents of Chiral Building blocks and process technology for the manufacture of Lisinopril and Benazepril.

2006 - Zydus Cadila forges alliance with French firm, Zydus Cadila receives USFDA approval for Simvastatin Tablets, Zydus Cadila to acquire Nutralite, India's largest selling cholesterol-free margarine, Sarabhai Zydus to roll out immuno-diagnostics kits

2008 - Zylus Cadila, Karo Bio to jointly develop new drugs, Zydus Cadila & Karo Bio of Sweden sign research agreement for a novel drug to treat inflammatory diseases. Zydus scores with first day launch of Venlafaxine Hydrochloride in the US.

2012 - Cadila Healthcare enters into a settlement and license agreement with Somaxon for Silenor, Cadila Healthcare gets USFDA nod for Aripiprazole orally disintegrating tablets.

2013 - Zydus Cadila receives tentative approval for Doxepin Hcl tablets, Zydus and IDRI
sign agreement for the development of IDRI’s Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar), Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalin Therapeutics, Zydus Pharmaceuticals (USA) Inc agreement with Warner Chilcott Company LLC.

2014 - Zydus and gilead enter into a generic licensing agreement to manufacture breakthrough treatment for hepatitis, Zydus launches world’s first biosimilar of Adalimumab, Cadila Healthcar - Lipaglyn - India's first NCE launched in the market, Zydus and IDRI sign agreement for the development of IDRI's, Zydus and Pieris Sign Broad Co-Development Alliance for Novel

2015 - Zydus Cadila has completed the single ascending dose (SAD) range, Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences, Cadila Healthcare Ltd has purchased the remaining 50 per cent shares of its joint venture firm, Zydus BSV Pharma Pvt Ltd (Zydus BSV), Cadila Healthcare Ltd has received the final approval from USFDA for Pyridostigmine Bromide Tablets, Cadila Healthcare Ltd has received the market authorisation from the United States Food and Drug Administration to market drug for the treatment of chronic pain or cancer related pain. Cadila Healthcare Ltd has received final approval from the USFDA to market Amiloride Hydrochloride Tablets USP, 5 mg, Zydus launches 'Tenglyn', the most affordable gliptin for diabetics in India. (Source : Dion Global Solutions Limited)

4. 8 Glenmark Pharma
Our Vision
To emerge as a leading integrated research–based global pharmaceutical company

Our Values

- **Achievement:** We value achievement of objectives and consistently strive towards our Vision, with perseverance.
- **Respect:** We respect all our stakeholders.
- **Knowledge:** We value knowledge such that it empowers our people to find innovative solutions to manage change

Glenmark is a well known brand in the Indian industry and has been operating in the market since 1977. It is a leading player in the dermatology segment. The India business contributes over 25% to the overall sales of the group. The business registered a compounded average growth of 16% for the last three years – This growth rate is significantly higher than industry growth rate.

Devlop of the Glenmark Pharma

1977 - The Company was incorporated on 18th, November, as Glenmark Pharmaceuticals Private Limited under the Companies Act, 1956, and became a deemed Public Company on July 1, 1990, then again became a private Company on September 27, 1990, the word Private was deleted on July 1, 1991 and became a Public Limited
Company on January 12, 1996. The Company is engaged in Research & Development, manufacturing and marketing of Pharmaceutical Formulations, domestically as well as overseas. The Company has a manufacturing facility at Satpur, Nasik. Besides manufacturing Oral Tablets, Liquids and Capsules it also equipped to manufacture Topicals - Creams, Lotions, Ointments and Powders. The plant has been awarded the WHO GMP Certificate indicative of the fact that the facilities and operations fully conform to the WHO requirements on quality standards.

1985 - Candid Mouth Paint was launched for oral thrush, targeted at Paediatricians. The Company launched Ascoril, a cough expectorant, and it is one of the most successful brands of the Company and is ranked 103rd as per ORG Aug’99-MAT.

1999 - The Company proposes to launch line extensions and new products to expand its product basket in the existing segments and also capitalise on its doctor penetration. The Company also proposes to establish a subsidiary in Canada, to penetrate the market. Altacef, Suprocin, Suprocin B, Scalpe and Elovera were launched during the year and have been the most successful product by the Company, recording high growth. Glenmark Pharmaceuticals, a Mumbai-based company, will be the first to test the waters from Industrial sector, viz., pharmaceuticals sector, while many other companies are waiting in the wing.

2004 - Glenmark Pharmaceuticals Inc, USA signs Development & Marketing Agreement with KV Pharmaceutical Company. Glenmark Pharmaceuticals has acquired Laboratories Klinger in Brazil for 2m through its wholly owned subsidiary in Brazil, Glenmark Farmaceutica.

2006 - Glenmark Pharmaceuticals - Glenmark USA acquires exclusive marketing rights to 3 additional generic products, Glenmark & Paul Capital Partners Sign Unique Royalty Deal for USD 27 mn to build US Generic Dermatology Portfolio Glenmark Pharmaceuticals US subsidiary inks agreement with Lehigh.

2009 - Glenmark Generics Limited (GGL) has received ANDA approval from the
United States Food and Drug Administration (U.S. FDA) for Alclometasone Dipropionate Cream, 0.05% and will commence marketing and distribution of this product in the U.S. market immediately. Glenmark Generics Limited's (GGL) US subsidiary has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Verapamil 240mg Extended Release tablet s and will immediately commence marketing and distribution in the U.S. market.


2014 - Glenmark merges its subsidiaries i.e. Glenmark Generics Ltd. (GGL) and Glenmark Access Ltd. (GAL) with GPL. Glenmark enters Oncology with the Discovery and the Initiation of IND enabling Studies of an innovative bispecific Antibody. Glenmark Pharmaceuticals inaugurates new Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland. US Food & Drug Administration (US FDA) has granted Glenmark its final acceptance for abbreviated new drug approval (ANDA) to the company.

2015 - Glenmark Pharmaceuticals Ltd announces approval and launch of Ashlyna TM Extended - Cycle Oral Contraceptive Tablets in the US. Glenmark Pharmaceuticals Ltd, Glenmark announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCl) Extended Release Tablets in the US.

(Source : Dion Global Solutions Limited)
4.9 GlaxoSmithKline Pharmaceuticals

**Registered Address**

Dr. Annie Besant Road,  
Mumbai  
Maharashtra  
400030

**Tel:** 022-24959595  
**Fax:** 022-24959494  
**Email:** askus@gsk.com  
**Website:** http://www.gsk-india.com  
**Group:** MNC Associate

**Registrars**

Karvy Computershare Private Ltd.  
Karvy Selenium Tower B, Plot no. 31-32,  
Gachibowli  
Financial District Hyderabad – 500032  
Telangana  
**Tel:** 040-23001153

---

**Our mission and strategy**

Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

At GSK, we have an evolving business model for a sustainable future. With the aim to increase growth, reduce risk, and improve our long-term financial performance, it is focused around five strategic priorities - grow a diversified global business, deliver more products of value, simplify the operating model, create a culture of individual empowerment, and build trust. Our strategic priorities are underpinned by our responsible business approach and we are continually listening to stakeholders to understand their expectations better.
Develop of the GlaxoSmithKline Pharmaceuticals

1924 - The Company was incorporated in India on 13th November under the name of H.J. Foster & Co. Limited as an Agency House for distributing the well-known Baby Food Glaxo of the then U.K. Company, Joseph Nathan & Co. two years later, the company became a wholly-owned subsidiary of Joseph Nathan & Co.

1986 - During the year, a new company was registered under the name of K G Gluco Biols Ltd. for the manufacture of products derived from maize in partnership with the Karnataka State Industrial Investment and Development Corporation Ltd. Also another company under the name of Vegepro Food & Feeds Ltd. was incorporated as a joint venture with Pradeshiya Industrial and Investment Corporation of U P Ltd. For implementaion of the soyabean project.

1995 - Glaxo India has entered into a marketing tie-up with Grampian Pharmaceuticals, a UK-based veterinary products maker. The company has struck a major deal with the UK-based 160 million pound company, Grampian Pharmaceuticals, which will boost Glaxo's presence in the veterinary market. The deal is part of tripartite agreement between Glaxo, Grampian and Global Parenterals, a Bangalore based pharma company. Glaxo entered fisheries market a few years ago through collaboration with a Canadian company to market Ovaprim, a fish spawning agent. Grampian products will complement Glaxo's range in these three segments of the market. The Company has launched special Respiratory, Dermatology and Hospital Sales teams to further sharpen its focus in these areas.

1996 - To improve the position of the Company in Oncology and Dermatology segments, specialised Onco and Dermo teams were formed. In order to tap the potential of the vast growing rural market, a Rural Marketing Team has been set up. The Company was awarded The Marketing Company of the Year award by the Institute of Marketing and Management, New Delhi. Chemical factories at Thane and Ankleshwar are being expanded to meet demand for local production and for exports. The Thane Factory was awarded the Glaxo Wellcome plc Chief Executive's Trophy for 1995 for Elimination of
Hazards through Innovative Process Development.

2001 - Glaxo and Allergan India have entered into a marketing alliance for the former's eye-care brand, ‘Catalin’. The Company with SmithKline Beecham Pharmaceuticals (India) Ltd. & also to approve the scheme of amalgamation and other related matters. Glaxo (India) and SmithKline Beecham Pharmaceuticals (India) have proposed to merge their Indian operations allotting one equity share of GIL for every two shares of SBPI held by the shareholders. The company has launched Celex, a clarithromycin anti-infective formulation under licence from and manufactured by Abbott India, Ventoride for asthma (combination of salbutamol and beclamethasone) and fluticasone cream, a corticosteroid.

2004 - GlaxoSmithKline Pharmaceuticals Ltd sells plot in Worli for Rs 107.6 crore to I-Ven Realty Ltd, a joint venture between ICICI Venture Funds Management Company Ltd and Oberoi Constructions. Receives prestigious “Multi Cultural Diversity Award” from GlaxoSmithKline Consumer Healthcare Limited, U.S. for the ‘Famili Vaccines’ programme, selected from 83 entries received from markets world-wide.

2008 - GlaxoSmithKline (GSK) Pharma has entered into a pact with Japan’s Astellas Pharma Inc for exclusive rights to sell the latter’s injectable anti-fungal agent Micafungin, branded Mycamine, in the local market. GlaxoSmithKline (GSK) Pharma has inked a co-promotion agreement with Daiichi Sankyo India Pharma Ltd for anti-hypertensive drug Olmesartan Medoxomil and its combination products.

2011 - GlaxoSmithKline Pharmaceuticals Limited announces launch of two drugs. Revolade™ (El trombopag olamine tablets,) oral platelet generator for chronic ITP Votrient™ (Pazopanib Hydrochloride Tablets) for advance renal cell carcinoma.

2012 - GlaxoSmithKline Pharmaceuticals Limited introduces Metered Dose Inhaler with dose counter. GlaxoSmithKline Pharmaceuticals observes World Asthma Day. A survey reveals women in India are putting work and social lives before their health when it comes to cervical cancer.
2015 - GlaxoSmithKline Pharmaceuticals Ltd. (‘GSK India’) announces completion of its transaction with Novartis Healthcare Pvt. Ltd. (‘Novartis India’) and acquires Novartis’ vaccines business and divests its marketed oncology portfolio to Novartis India.

(Source : Dion Global Solutions Limited)

4. 10 Divis Laboratories

Registered Address

1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Hyderabad
Telangana 500032

Registrars

Karvy Computershare Private Ltd.
Karvy Selenium Tower B
Plot no. 31-32, Gachibowli
Financial District Hyderabad - 500032
Telangana
Tel: 040-23001153

Tel: 040-23786300
Fax: 040-23786460
Email: mail@divislaboratories.com
Website: http://www.divislaboratories.com
Group: Not Applicable

Vision & Mission

To maintain leadership in custom synthesis of APIs and Intermediates for health care and life sciences industry and to be one of the top companies world-wide in the domain. To develop generic APIs for the late life cycle needs of the Industry.
Mission to Serve

To be a good corporate citizen and not only add value in our core competency areas of Pharma but also serve the community at large through social, educational and environmental initiatives that would establish strong foundations for a better tomorrow.

Develop of the Divis Laboratories

1990 - Divis Research Center (DRC) established.

1991-1993 - DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors.

1994 - Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year.


2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004.


2009 - Certified and Awarded for Best Green Belt Development, SURAKSHA PURASKAR for the year 2008, Divi's Laboratories has given the Bonus in the Ratio of 1:1

2011 - Divi’s Laboratories surged 3.5 percent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours.

2013 - Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per
equity share of Rs. 2/- face value for the year ended March 31, 20.

2014 - Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014.

2015 - Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1.

(Source : Dion Global Solutions Limited)

4.11 Torrent Pharmaceuticals

Registered Address
Torrent House,
Off Ashram Road,
Ahmedabad
Gujarat 380009
Tel: 079-26585090 079-26583060
Fax: 079-26582100
Email: investorservices@torrentpharma.com
Website: http://www.torrentpharma.com
Group: Torrent Group

Registrars
Karvy Computershare Private Ltd.
Plot No.17-24,
Madhapur Hyderabad - 500081
Telangana
Tel: 040-23420815, 23420816, 23420817
Fax: 040-23420814
Email: einward.ris@karvy.com
Website: http://www.karvy.com

Mission
We commit ourselves to total customer care by delivering world-class products and services.

Vision
To be the leader in the pharmaceutical industry
Core Values

We as Torrentians hail from diverse backgrounds and cultures. Each of us have different upbringing that influences our views, opinions, preferences, prejudices, beliefs etc. This diversity is our strength. We need to constantly build upon this strength, harnessed by our core values.

These core values, you will agree, help us develop a sense of trust, ownership and pride amongst each of our stakeholders who are associated with Torrent. It guides us in building a sustainable organization that can withstand the test of time.

Develop of the Torrent Pharmaceuticals

1972 - The Company was incorporated on 15th July, as a Private Limited Company by Shri Rajnikant C. Patel and his family members, and in June.

1982 - The company was acquired by Shri Uttamlal N. Mehta. The Company is primarily engaged in the manufacture of various Pharmaceuticals formulations and bulk drugs. The products of the Company enjoy good reputation and are well accepted in the market. The Company has taken up manufacture of bulk drugs as a strategic value added backward integration to its formulation activities.

1989 - On 28th June the Company became a deemed Public Company under the provisions of Section 43-A of the Act and by a Special Resolution passed on 25th July, 1992 at the Annual General Meeting, the Company became a Public Limited Company within the meaning of Section 3(1)(iv) of the act and adopted a new set of articles.

1992 - Torrent Laboratories Limited was amalgamated with the Company with effect from 1st April by an order of the Honourable High Court of Gujarat, dated 22nd December. The Company proposes to undertake an expansion-cum modernisation of its existing facilities, setting up facilities for manufacture of new products apart from setting up a separate in-house Research & Development Centre.

1993 - The Company proposes to modernize its present manufacturing facilities located at
Vatva and Chhatral to conform to the GMP requirements as also to incorporate the latest technology available in the field. Torrent Medi-Systems Limited (TMSL) was merged with the Company with effect from 1st April consequent to the scheme of amalgamation approved by the Honourable High Court of Gujarat.

1995 - During the year the Company launched a number of new products like Lomef (Lomefloxacin), Dilzem Inj. (Diltiazem), Depidol LA (Haliiperidiil Decanoate) Oncoden (Ondancetron), Nimotide (Nimodipne), Pefcin (Pefloxacin) which have gained wide acceptance in the pharmaceutical market. The Company proposes to launch new molecules to strengthen its product portfolio and to consolidate leadership in the relevant therapeutic segments. The Company has entered into a strategic alliance with Pfizer Inc. USA the fourth largest pharmaceutical company in the world.

1997 - The company has strategic alliances with world-renowned pharmaceutical giants like Sanofi, France, for cardio-vascular produces; and Novo Nordisk, Denmark, in the area of diabetic care. Torrent has become one of the largest exporters of medical formulations from India, with sales in over 70 countries and a network of overseas marketing offices.

1998 - Other new products introduced in the market include Normabrain 800 and Amlocar which have been well received by the medical fraternity. The company’s drug Lozapin for the treatment of resistant schizophrenia also is amongst the first time launch in the country. The Mehtas-controlled Torrent Pharmaceuticals Ltd is seeking tie-ups for molecular research in therapeutic segments such as anti-infectives, cardio-vascular and neuropsychiatry.

2003 - Torrent Pharma sets up wholly owned subsidiaries in Germany and Brazil. Torrent Pharma launches ‘Aripiprazole’ new antiseptic drug under the Brand name of Arip MT.
-a) New API manufacturing plant for catering to regulated markets
(b) New formulations facilities at one or more locations for catering to regulated markets & meeting the anticipated growth in the domestic market. ii) Incorporate a wholly owned subsidiary in USA.

2006 - Torrent Pharma Receives USFDA Approval, Torrent’s Azuca launches 2 new
blockbusters, Pregeb and Piopod, Entered into an in-licensing deal with Tasly of China to market its Cardiotonic pill in India, Torrent Pharmaceuticals Ltd has announced that the Company has launched Nexpro Fast (Immediate Release Esomeprazole), a Proton Pump Inhibitor (PPI), for the first time in India to treat peptic ulcers and GERD (Gastro Esophageal Reflux Disease).

2007 - Torrent unveils laxative in tablet form, Torrent Pharma launches CV pill, The world’s first ‘polypill’ in Cardiac care Indians to get slimmer and fitter: Torrent Pharma launches Rimoslim India’s first Rimonabant, Torrent Pharma launches Fibotab; India’s first bulk laxative in tablet form.

2011 - Torrent Pharma gets US FDA approval for alfuzosin hydrochloride extended release tablets. Board have recommended a normal annual dividend of Rs. 6 per equity share of Rs. 5/- each and a special dividend of Rs. 2.00 per equity share of Rs. 5/ each fully paid up.

2013 - Torrent has acquired Indian Branded Formulations Business of Elder. Torrent has recommended to issue bonus shares in the ratio of 1: 1 i.e. one equity bonus share for each fully paid up equity share.

2014 - Torrent enters into exclusive licensing agreement with Reliance Life Sciences for 3 biosimilars. Drug maker Torrent Pharma on Monday got an exemption from price control for one of its newly developed fixed dose combination (FDC) products.

2015 - Torrent Pharmaceuticals has completed acquisition of Zyg Pharma Pvt Ltd. Torrent Pharma has commenced commercial operations at its new plant in Dahej.

(Source : Dion Global Solutions Limited)
References:-
www.sunpharma.com
www.lupinpharmaceuticals.com
www.cipla.com
www.drreddys.com
www.aurobindo.com
www.glenmarkpharma.com
http://cadilapharma.com
http://india-pharma.gsk.com
www.divislabs.com
http://www.torrentpharma.com
www.moneycontrol.com
http://business.mapsofindia.com/indiacompany/pharmaceutical.html#sthash.nNqZvYqD.dpuf